RNACHIGH SIGNALFINANCIAL10-K

RNAC experienced a dramatic revenue collapse alongside substantially higher losses, while burning through nearly half of its cash position.

The company appears to have transitioned from a revenue-generating entity to a pure R&D operation, with revenue falling to minimal levels while operating losses expanded meaningfully. The substantial cash burn combined with increased R&D spending suggests the company is in an intensive development phase, but the financial runway has shortened considerably.

Comparing 2026-03-09 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

RNAC's financial profile shifted dramatically, with revenue collapsing to just $2.8M from $38.9M while net losses expanded substantially to $130.3M. The company burned through $87.5M in cash, reducing its position to $125.1M, even as R&D expenses grew 29% to $58.0M, indicating heavy investment in clinical development amid a challenging financial trajectory.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-92.8%
$38.9M$2.8M

Revenue declined 92.8% — significant demand weakness or market share loss warrants investigation.

Net Income
P&L
-68.3%
-$77.4M-$130.3M

Net income declined 68.3% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-41.1%
$212.6M$125.1M

Cash declined 41.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-40.3%
$216.6M$129.3M

Current assets declined 40.3% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-40%
$9.1M$5.5M

Capex reduced 40% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
-35%
$23.0M$14.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-31.9%
$435.0M$296.4M

Total assets contracted 31.9% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
+28.7%
$45.1M$58.0M

R&D investment increased 28.7% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+27.9%
$872K$1.1M

Receivables grew 27.9% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-13
ADDED
As of February 28, 2026, the registrant had 26,509,024 shares of common stock, par value $0.0001 per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 59 Item 7A.
Food and Drug Administration, or FDA, regulation of our product candidates; our ability to obtain and retain key executives and retain qualified personnel: developments relating to our competitors and our industry: any future payouts under the contingent value right, or CVR, issued to our holders of record as of the close of business on December 4, 2023; and our ability to monetize any of our legacy assets.
We leverage our proprietary technology and manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions.
Our cell therapies are designed to be dosed repeatedly like conventional drugs, administered in an outpatient setting and given without pre-treatment chemotherapy required with many conventional cell therapies.
These diseases are typically treated with immunosuppressant medications, such as steroids, biologics and non-steroidal agents such as methotrexate, CD19 directed therapies and intravenous immunoglobulin.
These treatments must be administered chronically and carry risks, including infection, osteoporosis and metabolic disease.
The treatment landscape within generalized myasthenia gravis, or MG, offers agents that block the complement pathway or inhibit the neonatal Fc receptor, or FcRn, that typically must be administered chronically.
Even with recent treatment advancements in the field of MG, we believe there remains a significant unmet need for outpatient treatments, administered over a short period of time, and can provide deep and durable clinical benefit.
Limitations of Current Biologic Treatments in Autoimmune Disease Currently approved biologic therapies for MG, such as complement inhibitors and FcRn inhibitors have improved treatment options.
REMOVED
As of February 28, 2025, the registrant had 25,907,101 shares of common stock, par value $0.0001 per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 56 Item 7A.
Food and Drug Administration, or FDA, regulation of our product candidates; our ability to obtain and retain key executives and retain qualified personnel; and developments relating to our competitors and our industry, including the impact of government regulation.
We leverage our proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Therefore, our mRNA cell therapies are distinguished by their capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies.
In a placebo-controlled Phase 2b clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit where we observed an average MG-ADL (Activities of Daily Living) reduction of 5.5 points at Month 4 with a third of patients achieving minimal symptom expression at Month 6 and 80% of participants reaching Month 12 maintained a clinically meaningful response.
Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable.
Autoimmune diseases are typically treated with immunosuppressant medications, such as steroids.
These treatments must be administered continually and carry risks, including infection, osteoporosis, and metabolic disease.
Newer agents that block the complement pathway or inhibit the neonatal Fc receptor, or FcRn, must also typically be administered continually.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →